[go: up one dir, main page]

MX2017008567A - Dnasa modificada y usos de la misma. - Google Patents

Dnasa modificada y usos de la misma.

Info

Publication number
MX2017008567A
MX2017008567A MX2017008567A MX2017008567A MX2017008567A MX 2017008567 A MX2017008567 A MX 2017008567A MX 2017008567 A MX2017008567 A MX 2017008567A MX 2017008567 A MX2017008567 A MX 2017008567A MX 2017008567 A MX2017008567 A MX 2017008567A
Authority
MX
Mexico
Prior art keywords
dnase
protein
modified
dna
modified dnase
Prior art date
Application number
MX2017008567A
Other languages
English (en)
Other versions
MX395742B (es
Inventor
Chen Zeltsburg Lilach
Ruderfer Ilya
Shulman Avidor
Fux Liat
Ugortsev Yulia
Neta Hagit
Gelley Sivan
Lavee Laviad Elad
Shaaltiel Yoseph
Original Assignee
Protalix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protalix Ltd filed Critical Protalix Ltd
Publication of MX2017008567A publication Critical patent/MX2017008567A/es
Publication of MX395742B publication Critical patent/MX395742B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21001—Deoxyribonuclease I (3.1.21.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan proteínas DNasa I modificadas en las que se modifican no celularmente uno o más aminoácidos de una proteína DNasa I. La proteína DNasa I modificada exhibe una actividad hidrolítica de ADN en presencia de actina y una actividad hidrolítica de ADN mejorada en comparación con una proteína DNasa I no modificada homóloga. También se proporcionan procedimientos para preparar la proteína DNasa I modificada y sus usos en, por ejemplo, la reducción de un contenido de ADN en el esputo y/o en el tratamiento de una enfermedad o una afección asociadas al exceso de ADN extracelular en un fluido, una secreción o un tejido de un sujeto.
MX2017008567A 2015-01-04 2016-01-04 Dnasa modificada y usos de la misma. MX395742B (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562099565P 2015-01-04 2015-01-04
US201562099560P 2015-01-04 2015-01-04
US201562163497P 2015-05-19 2015-05-19
US201562169724P 2015-06-02 2015-06-02
US201562247856P 2015-10-29 2015-10-29
PCT/IL2016/050003 WO2016108244A1 (en) 2015-01-04 2016-01-04 Modified dnase and uses thereof

Publications (2)

Publication Number Publication Date
MX2017008567A true MX2017008567A (es) 2018-04-26
MX395742B MX395742B (es) 2025-03-25

Family

ID=55442842

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017008567A MX395742B (es) 2015-01-04 2016-01-04 Dnasa modificada y usos de la misma.

Country Status (13)

Country Link
US (2) US11225648B2 (es)
EP (1) EP3240896A1 (es)
CN (1) CN107406837A (es)
AU (1) AU2016204793B2 (es)
BR (1) BR112017014433A2 (es)
CA (1) CA2970216A1 (es)
HK (1) HK1245822A1 (es)
IL (1) IL253208B2 (es)
MX (1) MX395742B (es)
NZ (1) NZ733912A (es)
RU (1) RU2017125957A (es)
WO (1) WO2016108244A1 (es)
ZA (1) ZA201704903B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1245822A1 (zh) 2015-01-04 2018-08-31 Protalix Ltd 一种经修饰的dnase及其应用
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
BR112019009925A2 (pt) 2016-11-17 2019-10-08 Iovance Biotherapeutics Inc método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer .
JP2021510539A (ja) 2018-01-16 2021-04-30 シーエルエス セラピューティクス リミテッドＣＬＳ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ デオキシリボヌクレアーゼ（ＤＮａｓｅ）活性を有する酵素の肝臓発現による疾患の処置
EP3821003A4 (en) * 2018-07-09 2022-07-20 Gro Biosciences Inc. Non-standard amino acid containing compositions and uses thereof
WO2020106709A1 (en) * 2018-11-19 2020-05-28 Gro Biosciences Inc. Human dnase for lung disease
WO2020198452A1 (en) * 2019-03-26 2020-10-01 Medicinal Genomics Corporation Methods of detecting microbial content in cannabis
JP2023545740A (ja) 2020-10-07 2023-10-31 プロタリクス リミテッド 長期活性ＤＮａｓｅ
WO2022178078A1 (en) 2021-02-19 2022-08-25 Theripion, Inc. Paraoxonase fusion polypeptides and related compositions and methods

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
ES2130120T3 (es) * 1988-12-23 1999-07-01 Genentech Inc Procedimiento para la preparacion de la adnasa humana.
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5394866A (en) 1991-03-05 1995-03-07 Aradigm Corporation Automatic aerosol medication delivery system and methods
DE69333443T2 (de) 1992-04-09 2005-03-24 Omron Healthcare Co., Ltd. Ultraschallzerstäuber
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5694919A (en) 1993-01-29 1997-12-09 Aradigm Corporation Lockout device for controlled release of drug from patient-activated dispenser
US5507277A (en) 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5888477A (en) 1993-01-29 1999-03-30 Aradigm Corporation Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin
JP3009224B2 (ja) * 1994-03-04 2000-02-14 ジェネンテック インコーポレイテッド 改良されたｄｎアーゼ液体溶液
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US5509404A (en) 1994-07-11 1996-04-23 Aradigm Corporation Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values
US5522385A (en) 1994-09-27 1996-06-04 Aradigm Corporation Dynamic particle size control for aerosolized drug delivery
SK284191B6 (sk) * 1995-02-24 2004-10-05 Genentech, Inc. Aktín-rezistentný variant humánnej DNázy I
US6348343B2 (en) * 1995-02-24 2002-02-19 Genentech, Inc. Human DNase I variants
US6391607B1 (en) * 1996-06-14 2002-05-21 Genentech, Inc. Human DNase I hyperactive variants
GB2316323B (en) 1996-06-20 1999-09-22 Aid Medic Ltd Dispensing system
AU6014098A (en) 1996-12-31 1998-07-31 Inhale Therapeutic Systems Aerosolized hydrophobic drug
US5855564A (en) 1997-08-20 1999-01-05 Aradigm Corporation Aerosol extrusion mechanism
US6397838B1 (en) 1998-12-23 2002-06-04 Battelle Pulmonary Therapeutics, Inc. Pulmonary aerosol delivery device and method
GB9903433D0 (en) 1999-02-15 1999-04-07 The Technology Partnership Plc Droplet generation method and device
US6962151B1 (en) 1999-11-05 2005-11-08 Pari GmbH Spezialisten für effektive Inhalation Inhalation nebulizer
DE10013093B4 (de) 2000-03-17 2005-12-22 Inamed Gmbh Vorrichtung zur kontrollierten Inhalation therapeutischer Aerosole
EP1249244A1 (en) 2001-04-13 2002-10-16 Universiteit Gent Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease
DE10123749A1 (de) 2001-05-16 2002-12-12 Inamed Gmbh Vorrichtung zum Verabreichen von Aerosolen
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US20030044493A1 (en) 2001-06-28 2003-03-06 Rettey David C. Container comprising edible manifold
RU2269356C2 (ru) 2003-07-14 2006-02-10 Дмитрий Дмитриевич Генкин Способ лечения онкологических заболеваний
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
WO2006130034A1 (fr) 2005-04-25 2006-12-07 Dmitry Dmitrievich Genkin Procede pour prolonger la duree de vie d'animaux ou de l'humain
WO2006006963A2 (en) 2004-04-02 2006-01-19 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Aerosol delivery systems and methods
WO2007131108A2 (en) 2006-05-03 2007-11-15 Tmi Laboratories International, Inc. Method to diagnose and increase fertility of mammalian semen using dnase as diagnostic marker and therapeutic agent
US20080131497A1 (en) 2006-09-28 2008-06-05 Perkins Walter R Formulations of DNase and Methods of Use Thereof
PT2086642E (pt) 2006-10-18 2014-09-30 Periness Ltd Dnase para o tratamento de subfertilidade masculina
US8871200B2 (en) 2006-11-28 2014-10-28 Cls Therapeutics Limited Method for treating human diseases associated with an increased deoxyribonucleic acid content in extracellular spaces of tissues and a medicinal preparation for carrying out said method
WO2011004476A1 (ja) 2009-07-09 2011-01-13 パイオニア株式会社 スピーカ装置
US20150010527A1 (en) 2012-02-01 2015-01-08 Protalix Ltd. Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy
HK1245822A1 (zh) 2015-01-04 2018-08-31 Protalix Ltd 一种经修饰的dnase及其应用

Also Published As

Publication number Publication date
CA2970216A1 (en) 2016-07-07
US20220106578A1 (en) 2022-04-07
CN107406837A (zh) 2017-11-28
BR112017014433A2 (pt) 2018-05-15
AU2016204793B2 (en) 2021-12-16
IL253208B2 (en) 2023-03-01
WO2016108244A1 (en) 2016-07-07
ZA201704903B (en) 2023-10-25
US11225648B2 (en) 2022-01-18
US11814657B2 (en) 2023-11-14
NZ733912A (en) 2023-04-28
MX395742B (es) 2025-03-25
AU2016204793A1 (en) 2017-08-10
US20180112201A1 (en) 2018-04-26
IL253208B (en) 2022-11-01
EP3240896A1 (en) 2017-11-08
RU2017125957A (ru) 2019-02-04
HK1245822A1 (zh) 2018-08-31
IL253208A0 (en) 2017-08-31

Similar Documents

Publication Publication Date Title
MX2017008567A (es) Dnasa modificada y usos de la misma.
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
CO2019002609A2 (es) Proteínas de unión recombinantes y sus usos
SV2018005781A (es) Proteinas de fusión gdf15 y usos de éstas
EP3607074A4 (en) REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS THERAPEUTIC PROTEINS, FOR EXAMPLE SUBCUTANEOUSLY
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
MX2023001119A (es) Variantes de enzimas y polinucleotidos que las codifican.
BR112017004349A2 (pt) terapia com gene de globina para o tratamento de hemoglobinopatias
BR112017003406A2 (pt) genoma de chromobacterium subtsugae
MX389093B (es) Composiciones y metodos para la glicosilacion de proteinas.
BR112016023304A2 (pt) célula hospedeira recombinante engendrada para superexpressar proteínas auxiliares
CR20170197A (es) Proteinas de variantes de secuencias de aminoacidos de cry1da1 activas para lepidópteros
BR112018067536A2 (pt) sistema de transpóson e métodos de uso
AR102272A1 (es) Polipéptidos insecticidas que tienen actividad de amplio espectro y usos de estos
BR112017001417A2 (pt) variantes de proteína de ligação ao fator h e métodos para uso das mesmas
BR112017013453A2 (pt) novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório
MX2024012898A (es) Proteinas de fusion de enzimas lisosomales terapeuticas dirigidas, formulaciones asociadas y usos de las mismas
BR112018007474A2 (pt) ?limpeza de membranas de filtração de água?
MX2020010932A (es) Enzimas quinureninasa humanas y sus usos.
BR112018005464A2 (pt) expressão de proteínas contendo fc
MX2019013458A (es) Disminucion de homocisteina mediada por enzimas humanas para el tratamiento de pacientes con hiperhomocisteinemia y homocistinuria.
BR112018009097A2 (pt) spodoptera frugiperda resistente a vip3a
MX2017007103A (es) Variantes de lipasa y polinucleotidos que las codifican.
BR112017003228A2 (pt) genes chromobacterium subtsugae